Risk-Adapted Neoadjuvant Chemoradiotherapy in Rectal Cancer?

Neoadjuvant chemoradiotherapy can be omitted in low-risk rectal cancer patients without compromising outcomes, but intensified in high-risk patients, new findings suggest.

Related Keywords

Munich , Bayern , Germany , Johnson Janssen , Merck Serono , Reinhard Ruppert , , Municipal Hospital , Intuitive Surgical , Colorectal Cancer , Chemotherapy , Radiation Oncology , Malignant Rectal Neoplasm , Rectal Cancer , Ancer Rectal , Metastasis , Radiation Dose , Neoadjuvant , Cancer , Alignant Neoplasia , Arcinoma , Cancer Risk , Distant Metastasis , Istant Metastases , Tumor , Hospitals ,